Opioid Agonist Treatment (OAT) Guidance During the COVID-19 Pandemic

Guidelines
by
The College of Physicians and Surgeons of Newfoundland and Labrador

Release Date

2020

Geography

Canada

Language of Resource

English

Full Text Available

Yes

Open Access / OK to Reproduce

No

Peer Reviewed

No

Objective

Provide clinical guidance to ensure the uninterrupted access to OAT medications for patients during the COVID-19 pandemic.

Findings/Key points

This document provides an interim guideline for the management of OAT. It addresses office visits, remote visits, carry doses and the frequency of urine drug testing during the COVID-19 pandemic in the light of the need for social distancing, self-isolation and quarantining.

Keywords

Clinical guidance
Harm reduction
About pharmacists
About prescribers